LPC
OACC

Lineage Point Capital’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Lineage Point Capital’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49M Buy
232,945
+300
+0.1% +$3.19K 0.51% 77
2026
Q1 		$2.47M Buy
232,645
+3
+0% +$32 0.6% 68
2025
Q4 		$2.46M Buy
+232,642
New +$2.46M 0.93% 47

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lineage Point Capital's OACC Position: Q2 2026 in Review

Lineage Point Capital increased its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 0.13% in Q2 2026, buying an estimated $3.19K and bringing the position to 232,945 shares worth $2.49M. The position accounts for 0.51% of the portfolio, ranked #77.

Lineage Point Capital first reported a position in OACC in Q4 2025 and has held it in 3 quarters since. 50 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • Lineage Point Capital held 232,945 shares of Oaktree Acquisition Corp III Life Sciences worth $2.49M as of Q2 2026.
  • Lineage Point Capital bought 300 Oaktree Acquisition Corp III Life Sciences shares in Q2 2026, an estimated $3.19K.
  • Oaktree Acquisition Corp III Life Sciences made up 0.51% of Lineage Point Capital's portfolio in Q2 2026, its #77 holding.
  • Lineage Point Capital first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 50 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on Lineage Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.